Trxade Group Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Tampa, fl, april 23, 2024 (globe newswire) -- trxade health, inc. (nasdaq: meds) (the “company”), announced that, on april 17, 2024, the company received a notice (the “notice”) from the nasdaq listing qualifications department (“nasdaq”) indicating that because the company had not yet filed its annual report on form 10-k for the 2023 fiscal year (the “form 10-k”), the company was not compliant with the timely filing requirement for continued listing under nasdaq listing rule 5250(c)(1) (the “listing rule”), which requires listed companies to timely file all required periodic reports with the securities and exchange commission.

Tampa, fl, march 06, 2024 (globe newswire) -- trxade health inc. (nasdaq: meds) (the “company”), announced that the company's board of directors has declared a special cash dividend of $8.00 per share of common stock. the special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the company's web-based market platform assets. the special cash dividend is payable to stockholders of record as of march 18, 2024, with the dividend being paid on or about march 22, 2024.

Tampa, fl, jan. 17, 2024 (globe newswire) -- trxade health, inc. (nasdaq: meds) (“trxade”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its quarterly report on form 10-q for the period ended september 30, 2023 (the “form 10-q”).

Tampa, fl, nov. 29, 2023 (globe newswire) -- trxade health, inc. (nasdaq: meds) (“trxade”), a parent company of a pharmaceutical business-to-business exchange platform, announced today that it received a notice of non-compliance from the nasdaq listing qualifications department (“nasdaq”) on november 21, 2023 notifying the company that, as a result of the company's failure to timely file its quarterly report on form 10-q for the period ended september 30, 2023 (the “form 10-q”), the company is not in compliance with nasdaq listing rule 5250(c)(1) (the “rule”), which requires listed companies to timely file all periodic financial reports with the u.s. securities and exchange commission (the “sec”).

Tampa, fl, oct. 17, 2023 (globe newswire) -- trxade health, inc. (nasdaq: meds) (“trxade”), a parent company of pharmaceutical business-to-business exchange platform, which recently merged with superlatus, inc. (“superlatus”), today reconfirms its commitment to pharmaceutical marketplace via its subsidiary trxade, inc. and is pleased to clarify its commitment to the pharmaceutical industry. trxade, inc., a subsidiary of trxade health, inc. (the “company”), will continue to focus on the pharmaceutical space. the company is dedicated to serving the pharmaceutical industry and its over 13,000 members, reinforcing its position as a key player in this critical sector, adding 199 new members to its marketplace in the third quarter of 2023.

Trxade Health (NASDAQ: MEDS ) stock is soaring higher on Tuesday after the U.S. health services IT company announced a major asset sale. According to a filing with the Securities and Exchange Commission (SEC), wholly-owned subsidiary Trxade, Inc. is going to sell virtually all of its assets to Micro Merchant Systems.

TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the second quarter 2023, after market close on August 14, 2023.

Trxade Health (NASDAQ: MEDS ) stock is falling on Tuesday after the company announced it would undergo a merger with Superlatus . That merger will see Trxade Health distribute 3,839,176 shares of MEDS stock to current shareholders in Superlatus.

One of the biggest movers in today's market is little-known health tech company TRxADE Health (NASDAQ: MEDS ). Shares of MEDS stock have rocketed more than 60% higher as of this writing on an otherwise uneventful day in the market.

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Prashant Patel - Interim Chief Financial Officer Suren Ajjarapu - Founder, Chairman and Chief Executive Officer Conference Call Participants Allen Klee - Maxim Group LLC Howard Halpern - Taglich Brothers, LLC Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

TRxADE (MEDS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.12 per share a year ago.

TAMPA, FL / ACCESSWIRE / May 5, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023.

TAMPA, FL / ACCESSWIRE / April 25, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 8, 2023.

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q4 2022 Earnings Conference Call March 27, 2023 5:30 PM ET Company Participants Prashant Patel - CFO Surendra Ajjarapu - Founder, Chairman and CEO Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?